Introduction
Anti-vascular endothelial growth factor (anti-VEGF) treatment has added a new dimension to the management of ischaemic ocular conditions. Various studies have demonstrated the usefulness of bevacizumab in the management of various retinal vascular pathologies like proliferative diabetic retinopathy [1] [2] [3] , choroidal neovascularisation, [4] [5] [6] , central retinal vein occlusion [7, 8] , and neovascular glaucoma [9, 10] .
Case Presentation
A 64-year-old, hypertensive female came with chief complaints of decreased vision in her right eye for 3 months.
On examination of the right eye, the vision was evaluated as counting fingers at 2 m; the intraocular pressure was 12 mm Hg. She had a clear cornea, good pseudophakia, and peripheral posterior capsular opacification. On fundus examination, a tortuous superotemporal vessel with an area of neovascularisation near the arteriovenous crossing and a subhyaloid haemorrhage inferior to the macula were noted. A clinical diagnosis of ischaemic branch retinal vein occlusion with retinal neovascularisation and subhyaloid haemorrhage was made, which was confirmed by fluorescein angiography.
In the superotemporal quadrant, fluorescein angiography demonstrated a tortuous vessel with an area of hyperfluorescence that increased in size and intensity in the late phase, suggestive of a leaking neovascular frond near the disc. In addition, capillary nonperfusion in the adjacent area was noted ( fig. 1 ).
The patient was informed of the potential risks and benefits of intravitreal bevacizumab, and after informed written consent, an intravitreal bevacizumab injection of 1.25 mg (0.05 ml) was given to her right eye. The procedure was carried out in the operation theatre, under all aseptic precautions.
Topical 0.5% proparacaine drops were instilled. Topical 5% betadine drops were instilled in the conjunctival sac 5 min before the injection. Bevacizumab 1.25 mg (0.05 ml) was taken into a 1-ml tuberculin syringe. Using a caliper, 3.5 mm temporal from the limbus was marked, and 1.25 mg (0.05 ml) bevacizumab was injected intravitreally with a 27-gauge needle. Immediately after the injection, a paracentesis was done through the limbus, and the eye was padded. Acetazolamide 250 mg was given to the patient. After 4 h, the pad was removed, and the intraocular pressure was taken, which was normal.
The patient was instructed to administer topical moxifloxacin 0.5% eye drops 3 times a day for a period of 8 days and was told to report immediately in case of any undesired event. The patient was evaluated on the first day; 1 week later, sectoral laser treatment was done, and the patient was again reviewed 4 weeks later.
No clinical evidence of inflammation, endophthalmitis, or any other ocular toxicity was observed during the follow-up period. Further, no significant drug-related side effects were detected.
On the first day of follow-up, the vision in her right eye was maintained at counting fingers at 2 m; the intraocular pressure was 14 mm Hg. Her right fundus revealed decreased tortuosity of the superotemporal vessel as well as a decrease in the associated neovascularisation.
After 1 week, the vision of her right eye improved to 20/125, her intraocular pressure was 14 mm Hg, and the fundus showed regression of neovascularisation. Most surprisingly, there was a marked decrease in the tortuosity and diameter of the affected retinal vascula-ture ( fig. 2 ). Measurements of the retinal vessel diameter of the superotemporal venule before and 1 week after the injection were made using the software available on the IMAGEnet program. Image registration is possible on the program so that the same location is selected during the follow-up visits. Data are summarised in table 1.
Discussion
Costa et al. [11] have reported a similar observation with a higher dose of intravitreal injections (2.0 mg, 0.08 ml) of bevacizumab. They observed that in addition to a decrease in the dye leakage from affected retinal and macular areas and within the optic disc, clear changes in the vascular retinal network morphology (diameter and tortuosity) were observed as early as 1 week after each antiangiogenic treatment. It is possible to have a reduction in the diameter and decreased venous tortuosity of the affected retinal vein in addition to regression of neovascularisation even with a bevacizumab dose of 1.25 mg (0.05 ml), as in our case.
Vascular effects of VEGF are believed to be mediated by nitric oxide, which is a potent vasodilator. Anti-VEGF agents might impair retinal blood flow by blocking the actions of VEGF on the retinal vessels [12] . Previous reports have suggested that anti-VEGF agents might be associated with ischaemic retinal changes following intraocular use [12] . Yokoyama et al. [13] reported a patient with extensive occlusion of retinal vessels 4 weeks after intracameral bevacizumab injection for neovascular glaucoma.
This case report demonstrates that intravitreal bevacizumab might induce retinal vasoconstriction; however, larger studies are required to elucidate the potential relationship between intravitreal bevacizumab and changes in the diameter of retinal vessels and to determine its statistical significance. 
